Alzheimer
Ac-KLVFF-NH2 (70%) - Ac-KLVFF-NH2 (95%) - Amyloid-beta (1-40) human - Amyloid-beta (1-40) human (HCl-salt) - Amyloid-beta (1-42) human - Amyloid-beta (1-42) human (HCl-salt) - Biotinylated Amyloid-beta (1-40) human - Biotinylated Amyloid-beta (1-42) human - Control peptide Amyloid-beta (40-1) human - Control peptide Amyloid-beta (42-1) human - DWGKGGRWRLWPGASGKTEA (70%) - DWGKGGRWRLWPGASGKTEA (95%) - FYLKVPSSLHHHHGRDKLVFFHHHH (70%) - FYLKVPSSLHHHHGRDKLVFFHHHH (95%) - HNHKLVFFHHQH (70%) - HNHKLVFFHHQH (95%) - KLVFF (70%) - KLVFF (95%) - MAQTFWLSIQGKTLYWQIRIYAID (70%) - MAQTFWLSIQGKTLYWQIRIYAID (95%) - NYSKMIFSHHHH (70%) - NYSKMIFSHHHH (95%) - PGRSPFTGKKLFNQEFSQDQ (70%) - PGRSPFTGKKLFNQEFSQDQ (95%) - qshyrhispaqv (D-amino acids) - RIIGL (70%) - RIIGL (95%)
Ac-KLVFF-NH2 (70%) 5 mg - P2256.7005
132,87 EUR
Package Size: 5 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
Ac-KLVFF-NH2 (95%) 1 mg - P2256.9501
132,87 EUR
Package Size: 1 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
Ac-KLVFF-NH2 (95%) 5 mg - P2256.9505
174,07 EUR
Package Size: 5 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
Amyloid-beta (1-40) human (HCl-salt) 1 mg - P2250.0001
333,72 EUR
Package Size: 1 mg
Amyloid-ß-peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid-ß-peptides, which form insoluble fibrils via self-assembly. The amyloid-ß-peptides are fragments of the broadly distributed, …
Amyloid-beta (1-40) human (HCl-salt) 5 mg - P2250.0005
1.321,49 EUR
Package Size: 5 mg
Amyloid-ß-peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid-ß-peptides, which form insoluble fibrils via self-assembly. The amyloid-ß-peptides are fragments of the broadly distributed, …
Amyloid-beta (1-40) human 1 mg - P2249.0001
201,88 EUR
Package Size: 1 mg
Amyloid-ß-peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid-ß-peptides, which form insoluble fibrils via self-assembly. The amyloid-ß-peptides are fragments of the broadly distributed, …
Amyloid-beta (1-40) human 5 mg - P2249.0005
897,13 EUR
Package Size: 5 mg
Amyloid-ß-peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid-ß-peptides, which form insoluble fibrils via self-assembly. The amyloid-ß-peptides are fragments of the broadly distributed, …
Amyloid-beta (1-42) human (HCl-salt) 1 mg - P2248.0001
333,72 EUR
Package Size: 1 mg
Amyloid-ß-peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid-ß-peptides, which form insoluble fibrils via self-assembly. The amyloid-ß-peptides are fragments of the broadly distributed, …
Amyloid-beta (1-42) human (HCl-salt) 5 mg - P2248.0005
1.321,49 EUR
Package Size: 5 mg
Amyloid-ß-peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid-ß-peptides, which form insoluble fibrils via self-assembly. The amyloid-ß-peptides are fragments of the broadly distributed, …
Amyloid-beta (1-42) human 1 mg - P2247.0001
271,92 EUR
Package Size: 1 mg
Amyloid-ß-peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid-ß-peptides, which form insoluble fibrils via self-assembly. The amyloid-ß-peptides are fragments of the broadly distributed, …
Amyloid-beta (1-42) human 5 mg - P2247.0005
1.215,40 EUR
Package Size: 5 mg
Amyloid-ß-peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid-ß-peptides, which form insoluble fibrils via self-assembly. The amyloid-ß-peptides are fragments of the broadly distributed, …
Biotinylated Amyloid-beta (1-40) human 1 mg - P2254.0001
396,55 EUR
Package Size: 1 mg
Biotinylated amyloid-ß-peptides: Biotinylated peptides are a useful tool in many important applications. Biotin has a strong affinity for avidin or streptavidin. This interaction can be used for qualitative and quantitative detection, labelling or immobilisation. The biotinylated amyloid-ß peptides are …
Biotinylated Amyloid-beta (1-40) human 5 mg - P2254.0005
1.599,59 EUR
Package Size: 5 mg
Biotinylated amyloid-ß-peptides: Biotinylated peptides are a useful tool in many important applications. Biotin has a strong affinity for avidin or streptavidin. This interaction can be used for qualitative and quantitative detection, labelling or immobilisation. The biotinylated amyloid-ß peptides are …
Biotinylated Amyloid-beta (1-42) human 1 mg - P2253.0001
633,45 EUR
Package Size: 1 mg
Biotinylated amyloid-ß-peptides: Biotinylated peptides are a useful tool in many important applications. Biotin has a strong affinity for avidin or streptavidin. This interaction can be used for qualitative and quantitative detection, labelling or immobilisation. The biotinylated amyloid-ß peptides are …
Biotinylated Amyloid-beta (1-42) human 5 mg - P2253.0005
1.842,67 EUR
Package Size: 5 mg
Biotinylated amyloid-ß-peptides: Biotinylated peptides are a useful tool in many important applications. Biotin has a strong affinity for avidin or streptavidin. This interaction can be used for qualitative and quantitative detection, labelling or immobilisation. The biotinylated amyloid-ß peptides are …
Control peptide Amyloid-beta (40-1) human 1 mg - P2252.0001
201,88 EUR
Package Size: 1 mg
Amyloid-ß-peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid-ß-peptides, which form insoluble fibrils via self-assembly. The amyloid-ß-peptides are fragments of the broadly distributed, …
Control peptide Amyloid-beta (40-1) human 5 mg - P2252.0005
897,13 EUR
Package Size: 5 mg
Amyloid-ß-peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid-ß-peptides, which form insoluble fibrils via self-assembly. The amyloid-ß-peptides are fragments of the broadly distributed, …
Control peptide Amyloid-beta (42-1) human 1 mg - P2251.0001
271,92 EUR
Package Size: 1 mg
Amyloid-ß-peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid-ß-peptides, which form insoluble fibrils via self-assembly. The amyloid-ß-peptides are fragments of the broadly distributed, …
Control peptide Amyloid-beta (42-1) human 5 mg - P2251.0005
1.217,46 EUR
Package Size: 5 mg
Amyloid-ß-peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid-ß-peptides, which form insoluble fibrils via self-assembly. The amyloid-ß-peptides are fragments of the broadly distributed, …
DWGKGGRWRLWPGASGKTEA (70%) 5 mg - P2258.7005
174,07 EUR
Package Size: 5 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
DWGKGGRWRLWPGASGKTEA (95%) 1 mg - P2258.9501
132,87 EUR
Package Size: 1 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
DWGKGGRWRLWPGASGKTEA (95%) 5 mg - P2258.9505
396,55 EUR
Package Size: 5 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
FYLKVPSSLHHHHGRDKLVFFHHHH (70%) 5 mg - P2261.7005
174,07 EUR
Package Size: 5 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
FYLKVPSSLHHHHGRDKLVFFHHHH (95%) 1 mg - P2261.9501
174,07 EUR
Package Size: 1 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
FYLKVPSSLHHHHGRDKLVFFHHHH (95%) 5 mg - P2261.9505
522,21 EUR
Package Size: 5 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
HNHKLVFFHHQH (70%) 5 mg - P2263.7005
132,87 EUR
Package Size: 5 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
HNHKLVFFHHQH (95%) 1 mg - P2263.9501
132,87 EUR
Package Size: 1 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
HNHKLVFFHHQH (95%) 5 mg - P2263.9505
396,55 EUR
Package Size: 5 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
KLVFF (70%) 5 mg - P2255.7005
132,87 EUR
Package Size: 5 mg
Biotinylated amyloid-ß-peptides: Biotinylated peptides are a useful tool in many important applications. Biotin has a strong affinity for avidin or streptavidin. This interaction can be used for qualitative and quantitative detection, labelling or immobilisation. The biotinylated amyloid-ß peptides are …
KLVFF (95%) 1 mg - P2255.9501
132,87 EUR
Package Size: 1 mg
Biotinylated amyloid-ß-peptides: Biotinylated peptides are a useful tool in many important applications. Biotin has a strong affinity for avidin or streptavidin. This interaction can be used for qualitative and quantitative detection, labelling or immobilisation. The biotinylated amyloid-ß peptides are …
KLVFF (95%) 5 mg - P2255.9505
174,07 EUR
Package Size: 5 mg
Biotinylated amyloid-ß-peptides: Biotinylated peptides are a useful tool in many important applications. Biotin has a strong affinity for avidin or streptavidin. This interaction can be used for qualitative and quantitative detection, labelling or immobilisation. The biotinylated amyloid-ß peptides are …
MAQTFWLSIQGKTLYWQIRIYAID (70%) 5 mg - P2264.7005
174,07 EUR
Package Size: 5 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
MAQTFWLSIQGKTLYWQIRIYAID (95%) 1 mg - P2264.9501
174,07 EUR
Package Size: 1 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
MAQTFWLSIQGKTLYWQIRIYAID (95%) 5 mg - P2264.9505
522,21 EUR
Package Size: 5 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
NYSKMIFSHHHH (70%) 5 mg - P2262.7005
132,87 EUR
Package Size: 5 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
NYSKMIFSHHHH (95%) 1 mg - P2262.9501
132,87 EUR
Package Size: 1 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
NYSKMIFSHHHH (95%) 5 mg - P2262.9505
396,55 EUR
Package Size: 5 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
PGRSPFTGKKLFNQEFSQDQ (70%) 5 mg - P2259.7005
174,07 EUR
Package Size: 5 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
PGRSPFTGKKLFNQEFSQDQ (95%) 1 mg - P2259.9501
132,87 EUR
Package Size: 1 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
PGRSPFTGKKLFNQEFSQDQ (95%) 5 mg - P2259.9505
396,55 EUR
Package Size: 5 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
qshyrhispaqv (D-amino acids) 1 mg - P2260.9501
174,07 EUR
Package Size: 1 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
qshyrhispaqv (D-amino acids) 5 mg - P2260.9505
522,21 EUR
Package Size: 5 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
RIIGL (70%) 5 mg - P2257.7005
132,87 EUR
Package Size: 5 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
RIIGL (95%) 1 mg - P2257.9501
132,87 EUR
Package Size: 1 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
RIIGL (95%) 5 mg - P2257.9505
174,07 EUR
Package Size: 5 mg
Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) …
| Show 1 to 45 (of in total 45 products) | Sites: 1 |
